Dr. Jonathan True Lin, MD

Dr. Lin practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. Lin's NPI, 1891060166, was assigned on March 20, 2012. Dr. Lin graduated from The Warren Alpert Medical School of Brown University in 2012. Dr. Lin's New York license number on file is 274952.

Dr. Lin's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. Lin's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. The medical group on file is The Rogosin Institute. Dmand AI also links Dr. Lin to 2 more clinical labs, 1 dialysis center and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 5 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Lin is board certified in internal medicine by the American Board of Internal Medicine. Dr. Lin has a license on file in New York.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances, kidney disease and kidney failure among the conditions Dr. Lin treats.

CMS data shows 1,541 Medicare services from Dr. Lin across 16 procedure codes in 2024, for 459 Medicare patients. Medicare paid $100,632 for them.

CMS counts 459 Medicare patients who saw Dr. Lin in 2024. The largest group is 65 to 74, with 161 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 41% are also on Medicaid. Their average risk score is 5.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 72, with 50% women.

In 2024, Dr. Lin wrote 1,479 Medicare Part D claims for 189 patients. 78% of them were for generic drugs. CMS names the drug for 1,217 of them, across 37 drugs with 11 or more claims each, at $289,425 in total drug cost. In 2023, CMS named 924 claims across 33 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Lin for performance year 2024, reported individually. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lin as offering telehealth.

Dmand AI links 3 papers to Dr. Lin, published from 2020 to 2023. The most frequent topics are COVID-19. Dr. Lin's most frequent co-authors are Oleh M. Akchurin, MD, Eric Thaddeus Caliendo, MD and Mary E. Choi, MD.

CMS Open Payments shows 11 general payments to Dr. Lin from 9 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 92% of the total. AstraZeneca Pharmaceuticals LP paid the most, $237.

Dr. Lin graduated from The Warren Alpert Medical School of Brown University in 2012.

Dr. Lin is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.